This renewal application requests support for pre- and post-doctoral trainees in an Integrated Cardiovascular Pathophysiology (ICVP) training program. Faculty mentors in the ICVP training program have their appointments within the Cardiovascular Research Center (Directed by Dr. Steven Houser, ICVP program director) or the Center for Translational Medicine (directed by Dr. Walter Koch, Co-Director of the ICVP program) at Temple University School of Medicine. The purpose of our program is to provide a broad based multidisciplinary training experience for pre- doctoral fellows, post-doctoral fellows and summer medical students in the area of integrative cardiovascular pathophysiology (ICVP). ICVP faculty members reside with many different basic science and clinical Departments, but their research laboratories are within the CVRC and CTM which are housed on two adjacent floors of a new medical research building. ICVP investigators/mentors have related interests in fundamental properties of the cardiovascular system and the aberrant changes in these properties that cause cardiovascular dysfunction in diseases including ischemic heart disease, hypertensive heart disease, atherosclerosis, ischemic vascular disease, metabolic syndrome and diabetic cardiovascular diseases. Graduate students and post-doctoral fellows will receive didactic training in human physiology and pathophysiology, complemented by advanced training in cellular and molecular biology and the appropriate use of animal models of human cardiovascular disease. Graduate student and fellow research projects will have basic and translational components. The students and fellows will be expected to investigate problems that go beyond a single molecule and address questions within the context of cardiovascular disease models. Different portions of these projects will be performed in the laboratories of different investigators, ensuring that students and fellows are exposed to different scientific approaches. All trainees will be involved in activities to enhance their grant and manuscript writing and oral communication skills. Group mentoring by junior and senior faculty will ensure trainees are well qualified to assume positions as leading investigators able to rapidly translate new knowledge into clinical practice. A variety of recruiting strategies will be used to attract a diverse group of trainees that reflect the diversity of our country. The goal is to graduate a diverse group of new Ph.Ds. and post-doctoral fellows that are able to fill a national need for new biomedical scientists to provide the next generation of therapies to reduce the impact of cardiovascular diseases..
Cardiovascular disease is the number one cause of death in the US. This proposal describes a training program in that seeks to train a diverse group of graduates students and post-doctoral fellows in the approaches they will need in order to develop novel therapies to reduce the impact of cardiovascular disease on our society.
|Harper, Shavonn C; Brack, Andrew; MacDonnell, Scott et al. (2016) Is Growth Differentiation Factor 11 a Realistic Therapeutic for Aging-Dependent Muscle Defects? Circ Res 118:1143-50; discussion 1150|
|Traynham, Christopher J; Hullmann, Jonathan; Koch, Walter J (2016) ""Canonical and non-canonical actions of GRK5 in the heart"". J Mol Cell Cardiol 92:196-202|
|Hullmann, Jonathan; Traynham, Christopher J; Coleman, Ryan C et al. (2016) The expanding GRK interactome: Implications in cardiovascular disease and potential for therapeutic development. Pharmacol Res 110:52-64|
|Grisanti, Laurel A; Traynham, Christopher J; Repas, Ashley A et al. (2016) ?2-Adrenergic receptor-dependent chemokine receptor 2 expression regulates leukocyte recruitment to the heart following acute injury. Proc Natl Acad Sci U S A 113:15126-15131|
|Wallner, Markus; Duran, Jason M; Mohsin, Sadia et al. (2016) Acute Catecholamine Exposure Causes Reversible Myocyte Injury Without Cardiac Regeneration. Circ Res 119:865-79|
|Traynham, Christopher J; Cannavo, Alessandro; Zhou, Yan et al. (2015) Differential Role of G Protein-Coupled Receptor Kinase 5 in Physiological Versus Pathological Cardiac Hypertrophy. Circ Res 117:1001-12|
|Smith, Shavonn C; Zhang, Xiaoxiao; Zhang, Xiaoying et al. (2015) GDF11 does not rescue aging-related pathological hypertrophy. Circ Res 117:926-32|
|Trappanese, Danielle M; Liu, Yuchuan; McCormick, Ryan C et al. (2015) Chronic ?1-adrenergic blockade enhances myocardial ?3-adrenergic coupling with nitric oxide-cGMP signaling in a canine model of chronic volume overload: new insight into mechanisms of cardiac benefit with selective ?1-blocker therapy. Basic Res Cardiol 110:456|
|Duran, Jason M; Makarewich, Catherine A; Trappanese, Danielle et al. (2014) Sorafenib cardiotoxicity increases mortality after myocardial infarction. Circ Res 114:1700-1712|
|Tilley, Douglas G; Zhu, Weizhong; Myers, Valerie D et al. (2014) ?-adrenergic receptor-mediated cardiac contractility is inhibited via vasopressin type 1A-receptor-dependent signaling. Circulation 130:1800-11|
Showing the most recent 10 out of 34 publications